1-(4-甲基苯基)-2-氧代-3-吡咯烷羧酸 | 618070-29-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-(4-甲基苯基)-2-氧代-3-吡咯烷羧酸
• 中文别名: 1-(4-甲基苯基)-2-氧代吡咯烷-3-羧酸
• 英文名称: 2-oxo-1-(p-tolyl)-pyrrolidine-3-carboxylic acid
• 英文别名: N-(4-methylphenyl)-2-oxo-pyrrolidine-3-carboxylic acid；1-(4-Methylphenyl)-2-oxopyrrolidine-3-carboxylic acid
• CAS: 618070-29-4
• 化学式: C₁₂H₁₃NO₃
• mdl: MFCD03932870
• 分子量: 219.24
• InChiKey: BQAYIKBVMPQAFU-UHFFFAOYSA-N

物化性质

• 熔点：
  132-134 °C(Solv: ethanol (64-17-5))
• 沸点：
  518.5±50.0 °C(Predicted)
• 密度：
  1.297±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-(4-甲基苯基)-2-氧代-3-吡咯烷羧酸 在 sodium tetrahydroborate 、 碘 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 四氢呋喃 、 苯 为溶剂， 反应 10.0h， 生成 1-(4-methylphenyl)-3-formyl-1H-pyrrole
  参考文献：
  名称：

  Sodium borohydride–iodine mediated reduction of γ-lactam carboxylic acids followed by DDQ mediated oxidative aromatisation: a simple approach towards N-aryl-formylpyrroles and 1,3-diaryl-formylpyrroles

  摘要：

  A simple methodology for the conversion of substituted N-aryl-gamma-lactam 2/3-carboxylic acids to substituted N-aryl-2/3-formyl-pyrroles has been developed. Several N-aryl-gamma-lactam 2/3-carboxylic acids were reduced to substituted (N-aryl-pyrroliden-2/3-yl)-methanols in good yields by using the NaBH4-I-2 system. Aromatisation and in situ oxidation of these alcohols using DDQ produced N-aryl-2/3-formyl-pyrroles, which act as key starting material and intermediates in the synthesis of several bioactive compounds. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2007.01.058
• 作为产物：
  描述：

  1,1-环丙烷二甲酸环异亚丙酯 、 乙烷,三氯氟- 以 乙腈 为溶剂， 反应 48.5h， 以87%的产率得到1-(4-甲基苯基)-2-氧代-3-吡咯烷羧酸
  参考文献：
  名称：

  二螺吲哚-β-内酰胺：通过施陶丁格烯酮亚胺环加成合成和生物学评价

  摘要：

  在这项工作中，我们首次采用一锅施陶丁格烯酮-亚胺环加成优化方法，以 N-芳基-2-氧代-吡咯烷-3-羧酸作为烯酮源合成二螺吲哚-β-内酰胺。二氢吲哚-2-酮与β-内酰胺环的螺结合被认为能够为所得支架提供稳定性和广泛的功能化。获得的二哌氧吲哚在 A549、MCF7、HEK293 和 VA13 细胞系的 MTT 测试中显示出中等细胞毒性，其中一种化合物显示出对大肠杆菌菌株 LPTD 的抗菌活性。

  DOI：

  10.3390/ijms23126666

文献信息

• [EN] INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] DÉRIVÉS D'INDOLAMIDE ET COMPOSÉS ASSOCIÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DES MALADIES NEURODÉGÉNÉRATIVES
  申请人：UNIV LEUVEN KATH

  公开号：WO2010142801A1

  公开（公告）日：2010-12-16

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  本发明提供了新型化合物，以及这些新型化合物作为药物的使用，特别是用于预防或治疗神经退行性疾病，更具体地是一些神经系统疾病，例如统称为tauopathies的疾病，以及以细胞毒性α-突触核蛋白淀粉样蛋白生成为特征的疾病。本发明还涉及将所述新型化合物用于制造用于治疗此类神经退行性疾病的药物。本发明还涉及包括所述新型化合物的药物组合物，以及制备所述新型化合物的方法。
• INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Griffioen Gerard

  公开号：US20120083475A1

  公开（公告）日：2012-04-05

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  该发明提供了新型化合物，以及这些新型化合物用作药物，特别是用于预防或治疗神经退行性疾病，更具体地说是某些神经系统疾病，例如被统称为tau病理学的疾病，以及由细胞毒性α-突触蛋白淀积所特征的疾病。本发明还涉及使用这些新型化合物制备治疗这种神经退行性疾病的药物。本发明还涉及包括这些新型化合物的制药组合物，以及制备这些新型化合物的方法。
• Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases
  申请人：Griffioen Gerard

  公开号：US08618138B2

  公开（公告）日：2013-12-31

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  本发明提供了新型化合物及其用作药物的新型化合物，更具体地用于预防或治疗神经退行性疾病，更具体地用于某些神经系统疾病，如被称为tau病变的疾病和由细胞毒性α-突触核蛋白淀积引起的疾病。本发明还涉及使用所述新型化合物制备用于治疗此类神经退行性疾病的药物。本发明还涉及包括所述新型化合物的制药组合物以及制备所述新型化合物的方法。
• Sodium borohydride–iodine mediated reduction of γ-lactam carboxylic acids followed by DDQ mediated oxidative aromatisation: a facile entry to N-aryl-formylpyrroles
  作者：Pranab Haldar、Joyram Guin、Jayanta K. Ray

  DOI：10.1016/j.tetlet.2004.12.107

  日期：2005.2

  A simple methodology for the conversion of substituted N-aryl-gamma-lactam 2/3-carboxylic acids to substituted N-aryl-2/3-formyl-pyrroles has been developed. Several N-aryl-gamma-lactam 2/3-carboxylic acids were reduced to substituted (N-arylpyri-olidine-2/3-yl)-methanols in good yields at room temperature using sodium borohydride-iodine. Controlled oxidation and aromatisation of these alcohols using DDQ produced N-aryl-2/3-formyl-pyrroles. (C) 2004 Elsevier Ltd. All rights reserved.
• Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases
  申请人：Katholieke Universiteit Leuven, K.U. Leuven R&D

  公开号：US20190054068A1

  公开（公告）日：2019-02-21

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.